Early trial results of VYN201 show success in vitiligo

VYN201 showed positive effects on biomarkers of vitiligo in a phase 1b trial, VYNE Therapeutics announced in a press release.
A pan-bromodomain BET inhibitor, VYN201 is designed to be a locally administered “soft” drug addressing inflammatory cell signaling pathways.
The 16-week, open label, phase 1b trial included 29 patients with active nonsegmental vitiligo who were randomly assigned to receive one of three doses of topical VYN201 — 0.5%, 1% or 2% — to use on one lesion once daily.
Biopsies taken before treatment and at 8 weeks were analyzed for vitiligo-associated

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart